Mereo BioPharma Group Plc (MREO)
0.3499
-0.03
(-6.74%)
USD |
NASDAQ |
Oct 09, 16:00
0.344
-0.01
(-1.69%)
Pre-Market: 20:00
Mereo BioPharma Group Cash from Operations (Quarterly) : -6.048M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -6.048M |
| March 31, 2026 | -4.305M |
| December 31, 2025 | -7.670M |
| September 30, 2025 | -7.256M |
| June 30, 2025 | -7.756M |
| Date | Value |
|---|---|
| March 31, 2025 | -8.361M |
| December 31, 2024 | -9.329M |
| September 30, 2024 | -7.619M |
| June 30, 2024 | -7.914M |
| March 31, 2024 | -7.986M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Biodexa Pharmaceuticals Plc | -- |
| NuCana Plc | -2.571M |
| BioNTech SE | 12.56M |
| Silence Therapeutics Plc | 1.548M |
| Autolus Therapeutics Plc | -25.16M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.0004M |
| Free Cash Flow | -25.58M |
| Free Cash Flow Per Share (Quarterly) | -0.0376 |
| Free Cash Flow to Equity (Quarterly) | -7.079M |
| Free Cash Flow to Firm (Quarterly) | -6.049M |
| Free Cash Flow Yield | -45.67% |